356 related articles for article (PubMed ID: 2964811)
1. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
2. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
3. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
[TBL] [Abstract][Full Text] [Related]
4. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
[TBL] [Abstract][Full Text] [Related]
5. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
Yoshida M; Murai H; Miura S
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
[TBL] [Abstract][Full Text] [Related]
7. [Steroid hormone receptors in breast cancer].
Nomura Y
Rinsho Byori; 1990 Jan; 38(1):26-30. PubMed ID: 2308219
[TBL] [Abstract][Full Text] [Related]
8. Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancer.
Iino Y; Takeo T; Sugamata N; Aoyagi H; Takai Y; Takei H; Ando T; Koibuchi Y; Yokoe T; Ohwada S
Anticancer Res; 1995; 15(3):1061-4. PubMed ID: 7645926
[TBL] [Abstract][Full Text] [Related]
9. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.
Lorenz I; Mechl Z
Neoplasma; 1985; 32(1):119-24. PubMed ID: 3157070
[TBL] [Abstract][Full Text] [Related]
10. [Histochemical and biochemical assays of estrogen receptors in breast cancer and significance of endocrine therapy].
Tominaga T
Gan No Rinsho; 1983 May; 29(6):628-31. PubMed ID: 6308307
[TBL] [Abstract][Full Text] [Related]
11. Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy.
Fernandez MD; Alaghband-Zadeh J; Burn JI
Clin Oncol; 1983 Sep; 9(3):245-50. PubMed ID: 6616999
[TBL] [Abstract][Full Text] [Related]
12. [Value of hormone therapy in metastasizing breast cancer].
Samonigg H
Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208
[TBL] [Abstract][Full Text] [Related]
13. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
14. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
Mauriac L; Durand M; Bonichon F; Chauvergne J
Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
[TBL] [Abstract][Full Text] [Related]
15. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
16. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
17. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
Morgan LR; Schein PS; Woolley PV; Hoth D; Macdonald J; Lippman M; Posey LE; Beazley RW
Cancer Treat Rep; 1976 Oct; 60(10):1437-43. PubMed ID: 191185
[TBL] [Abstract][Full Text] [Related]
19. Effective sequential administration of tamoxifen and medroxyprogesterone acetate for 7,12-dimethylbenz[a-anthracene-induced rat mammary tumors in relation to hormone receptors.
Tominaga T; Yoshida Y; Kitamura M; Kosaki G
Jpn J Cancer Res; 1985 Nov; 76(11):1120-5. PubMed ID: 2935517
[TBL] [Abstract][Full Text] [Related]
20. Hormone receptors and Japanese breast cancer.
Matsumoto K; Kitamura Y; Sugano H
Acta Pathol Jpn; 1982; 32 Suppl 1():145-54. PubMed ID: 6764994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
